NCT06715579 Cardiac Angiosarcoma International Registry
| NCT ID | NCT06715579 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Immune Oncology Research Institute |
| Condition | Cardiac Angiosarcoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 500 participants |
| Start Date | 2025-05-01 |
| Primary Completion | 2035-05 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 500 participants in total. It began in 2025-05-01 with a primary completion date of 2035-05.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Primary cardiac angiosarcomas (PCA) are highly aggressive malignant heart tumors arising from the endothelial cells (ECs) lining the blood vessels of the heart and account for approximately 25%-30% of all primary cardiac malignancies. It is considered to be the most fatal and aggressive primary cardiac malignancy. This international registry aims to establish a large multicenter database of patients with cardiac angiosarcoma. Our objectives are: 1. Collect clinical data, including demographics, medical history, treatments, and outcomes, to build a comprehensive database. 2. Analyze data to evaluate and identify genetic, environmental, or lifestyle risk factors for cardiac angiosarcoma. 3. Evaluate the effectiveness of various treatments (surgery, chemotherapy, immunotherapy, radiation) to inform best practices. 4. Develop evidence-based guidelines and recommendations for prevention, diagnosis, treatment, and management based on registry data.
Eligibility Criteria
Inclusion Criteria: * Histological Confirmation: A confirmed diagnosis of cardiac angiosarcoma through histopathological examination, including subtypes such as hemangiosarcoma and epithelioid hemangiosarcoma. * Diagnosis Timing: Eligible patients must have been diagnosed between January 2015 and January 2035. * Geographical Representation: Participants should be from diverse geographical locations to ensure a comprehensive understanding of the disease across different populations. * Treatment Status: Patients who have received any treatment (surgery, chemotherapy, immunotherapy or radiation) for cardiac angiosarcoma may be included to evaluate treatment outcomes. * Informed Consent: For prospective patients, informed consent must be obtained before they are included in the registry. * Clinical Data Availability: Relevant clinical data, including demographics, tumor characteristics (size, location), treatment regimens, and outcomes, must be available for analysis. * Follow-Up Willingness: Participants should be willing to undergo follow-up assessments as part of the registry's data collection efforts. Exclusion Criteria: * Patients who decline to provide informed consent. * Cases where cardiac involvement is secondary to another primary malignancy
Contact & Investigator
Shushan Hovsepyan, MD
PRINCIPAL INVESTIGATOR
Immune Oncology Research Institute, Yerevan, Armenia
Frequently Asked Questions
Who can join the NCT06715579 clinical trial?
This trial is open to participants of all sexes, studying Cardiac Angiosarcoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06715579 currently recruiting?
Yes, NCT06715579 is actively recruiting participants. Contact the research team at aharon3tsaturyan@gmail.com for enrollment information.
Where is the NCT06715579 trial being conducted?
This trial is being conducted at Yerevan, Armenia.
Who is sponsoring the NCT06715579 clinical trial?
NCT06715579 is sponsored by Immune Oncology Research Institute. The principal investigator is Shushan Hovsepyan, MD at Immune Oncology Research Institute, Yerevan, Armenia. The trial plans to enroll 500 participants.